Breaking News Instant updates and real-time market news.

NVS

Novartis

$78.96

-0.29 (-0.37%)

, JNJ

Johnson & Johnson

$118.13

0.86 (0.73%)

14:40
10/02/16
10/02
14:40
10/02/16
14:40

Novartis reports multiple data sets on psoriasis therapy Cosentyx

Novartis (NVS) announced new data showing Cosentyx, or secukinumab delivers efficacy in patients with moderate to severe plaque psoriasis out to four years of treatment. These data come from the extension study of the Phase III SCULPTURE trial. Results were presented for the first time at the European Academy of Dermatology and Venereology Congress. SCULPTURE extension patients received the same blinded maintenance treatment regimen and dose up to the end of Year 3. In the fourth year, the study became open label. All results presented are for the Cosentyx 300 mg every 4 weeks group. Almost clear skin -- PASI 90 -- was achieved by 68.5% of patients at Year 1 and 61.9% of patients at Year 3, and was maintained at Year 4 in 66.4% of patients. Completely clear skin -- PASI 100 -- was achieved by 43.8% of patients at Year 1 and 41.7% of patients at Year 3, and was maintained at Year 4 in 43.5% of patients. The average improvement of psoriasis as measured by the PASI score was maintained at over 90% after 4 years of treatment. The historic standard goal of treatment, PASI 75 skin clearance, was achieved by 88.9% of patients at Year 1 and 78.4% of patients at Year 3, and was maintained by 88.5% of patients at Year 4. The most common adverse events at Year 4 were nasopharyngitis -- 12.1% -- and upper respiratory tract infection -- 3.5% -- and were similar to those observed at Year 1. Also presented at EADV were results from the GESTURE study demonstrating the strength of Cosentyx versus placebo in patients with moderate to severe palmoplantar plaque psoriasis. At Week 16, about 40% of patients achieved clear or almost clear palms and soles with Cosentyx 300 mg every 4 weeks, which continued to improve with approximately 60% of patients achieving clear or almost clear palms and soles at Week 80. AEs were reported in 47 of the 69 patients receiving Cosentyx and 27 of the 68 patients receiving placebo at Week 80. Additional data presented at EADV from a study in moderate to severe scalp psoriasis showed Cosentyx demonstrated superior efficacy compared to placebo. In the study, Psoriasis Scalp Severity Index 90 responses were achieved by a significantly greater percentage of patients receiving Cosentyx 300 mg -- 52.9% -- than placebo -- 2.0% -- at Week 12. No serious AEs were reported with Cosentyx. The company noted that newly published data also show Cosentyx delivers superior, long-lasting skin clearance versus Stelara, or ustekinumab, for up to 1 year in patients with moderate-to-severe psoriasis: 76% for Cosentyx vs. 61% for Johnson & Johnson's (JNJ) Stelara at 52 weeks.

NVS

Novartis

$78.96

-0.29 (-0.37%)

JNJ

Johnson & Johnson

$118.13

0.86 (0.73%)

  • 07

    Oct

  • 18

    Oct

  • 06

    Nov

NVS Novartis
$78.96

-0.29 (-0.37%)

08/31/16
LEER
08/31/16
NO CHANGE
Target $61
LEER
Outperform
Teva price target lowered to $61 from $66 at Leerink
Leerink analyst Jason Gerberry lowered his price target for Teva (TEVA) to $61 from $66 on loss of Copaxone patent challenge as an upside catalyst. The analyst believes Teva's share price implies a generic entrant sometime in the second half of 2017 after losing an Inter Partes Review decision on two Copaxone 40mg anchor patents. In order to mitigate EPS downside in 2017-2018 and eliminate business uncertainty, Gerberry thinks the company should settle its Copaxone patent dispute with Novartis (NVS) and Momenta (MNTA), which he sees as "the most credible" generic threat. The analyst reiterates an Outperform rating on Teva's shares.
08/31/16
PIPR
08/31/16
NO CHANGE
PIPR
Piper's Schimmer unsure of impact from Novartis CAR-T shakeup
Piper Jaffray analyst Joshua Schimmer said he's struggling with the implications of the news that Novartis (NVS) is reportedly eliminating its Cell and Gene Therapy unit as a stand-alone entity, which is primarily focused on development of CAR-T and adoptive immunotherapies. On the one hand, removing a leading competitor is a positive for the rest of the field, Schimmer tells investors in a research note. On the other hand, the move by Novartis could signal "significant challenges" in the field, the analyst adds. Schimmer continues to prefer companies "with unique and differentiated approaches," namely Bellicum Pharmaceuticals (BLCM), Cellectis (CLLS), Lion Biotechnologies (LBIO), Amgen (AMGN), Celgene (CELG) and bluebird bio (BLUE). Juno Therapeutics (JUNO) and Kite Pharma (KITE) are down 6% and 5%, respectively, in midday trading.
09/02/16
LEER
09/02/16
NO CHANGE
LEER
Outperform
Teva third Copaxone patent invalidated as expected, says Leerink
Leerink analyst Jason Gerberry says Teva (TEVA) suffered a largely expected loss in its Copaxone 40mg patent battle, with the Patent Trial and Appeal Board, or PTAB, ruling a third patent invalid. The analyst believes the company will likely appeal the loss, along with PTAB rulings rendered last week that other Copaxone patents were invalid. Gerberry sees the bull case scenario of Teva securing patent exclusivity of the Copaxone 40mg as unlikely and says a settlement with Momenta (MNTA) and Novartis (NVS) is the most logical course of action to mitigate 2017-2018E EPS risk. He reiterates an Outperform rating on Teva's shares.
09/20/16
CHDN
09/20/16
INITIATION
Target $95
CHDN
Buy
Novartis initiated with a Buy at Chardan
Chardan initiated Novartis with a Buy and a $95 price target.
JNJ Johnson & Johnson
$118.13

0.86 (0.73%)

08/18/16
UBSW
08/18/16
NO CHANGE
Target $137
UBSW
Buy
Johnson & Johnson remains a top large cap pick, says UBS
UBS analyst Matt Miksic said Johnson & Johnson remains a top large cap diversified pick for the year. The analyst said yesterday's court ruling that invalidated the company's Remicade patent was expected and could delay the Q4 biosimilar launch but its robust pharma pipeline remains under-appreciated and should make up the difference. He said he continues to see further clarity regarding potential U.S. biosimilar competition for Remicade as positive for the stock. Miksic reiterated his Buy rating and $137 price target on Johnson & Johnson shares.
08/24/16
JEFF
08/24/16
NO CHANGE
Target $210
JEFF
Buy
Cooper Companies estimates raised at Jefferies after doctor survey
Jefferies analyst Anthony Petrone reports that the firm's survey of 52 new optometry practices suggest continued gains in dailies and stable share in monthlies for Cooper Companies (COO) and that Johnson & Johnson's (JNJ) Acuvue Vita is off to slow start. Based on the survey results, and a "significant" foreign exchange tailwind, Petrone raised his estimates for Cooper and increased his price target on the shares to $210 from $190. The firm has a Buy rating on Cooper shares.
09/19/16
JEFF
09/19/16
NO CHANGE
Target $48
JEFF
Buy
Abbott unit sale does not impact Alere transaction, says Jefferies
Jefferies analyst Jeffrey Holford believes Abbott's (ABT) sale of its Medical Optics business to Johnson & Johnson (JNJ) does not imply an increased probability that the Alere (ALR) deal will close. After speaking to Abbott management, Holford thinks the proceeds from the sale are more likely to be targeted towards the St. Jude Medical (STJ) acquisition. He believes that deal has a higher probability of closing than Alere. Holford has a Buy rating on Abbott with a $48 price target.
09/19/16
LEER
09/19/16
NO CHANGE
LEER
Abbott, Johnson & Johnson transaction positive for both companies, says Leerink
Leerink analyst Danielle Antalffy says the sale of Abbott's (ABT) Medical Optics ophthalmology business to Johnson & Johnson (JNJ) is positive for both companies. The deal strengthens Abbott's balance sheet and eliminates the need for a previously expected $3B capital raise, and adds a key component to Johnson & Johnson's already-strong vision care franchise, the analyst notes.

TODAY'S FREE FLY STORIES

16:45
01/17/18
01/17
16:45
01/17/18
16:45
General news
Treasury TIC flows: foreign accounts bought $33.8 B in total U.S. assets »

Treasury TIC flows:…

VZ

Verizon

$51.72

0.06 (0.12%)

16:43
01/17/18
01/17
16:43
01/17/18
16:43
Hot Stocks
Verizon to record cumulative adjustment to retained earnings during 1Q18 »

Verizon said in a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

VZ

Verizon

$51.72

0.06 (0.12%)

16:42
01/17/18
01/17
16:42
01/17/18
16:42
Hot Stocks
Verizon sees $4.10 impact to FY17 EPS after tax reform »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

BELFA

Bel Fuse

, BELFB

Bel Fuse

$24.70

0.25 (1.02%)

16:39
01/17/18
01/17
16:39
01/17/18
16:39
Earnings
Bel Fuse anticipates Q4 revenue $120M, 1 estimate $124M »

The company's…

BELFA

Bel Fuse

BELFB

Bel Fuse

$24.70

0.25 (1.02%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

16:37
01/17/18
01/17
16:37
01/17/18
16:37
General news
API crude inventories for week of January 12 »

API reports that crude…

SLM

Sallie Mae

$11.49

0.02 (0.17%)

16:36
01/17/18
01/17
16:36
01/17/18
16:36
Earnings
Sallie Mae sees initial FY18 EPS 97c-$1.01, consensus $1.04 »

Sees FY18 private…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

AMGP

Antero Midstream GP

$20.89

-0.11 (-0.52%)

16:36
01/17/18
01/17
16:36
01/17/18
16:36
Hot Stocks
Antero Midstream GP provides distribution guidance for 2018 through 2022 »

Antero Midstream GP…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

AR

Antero Resources

16:36
01/17/18
01/17
16:36
01/17/18
16:36
Hot Stocks
Antero Resources sees FY18 CapEx $1.45B »

Antero's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

AR

Antero Resources

16:35
01/17/18
01/17
16:35
01/17/18
16:35
Hot Stocks
Antero Resources sees Q4 net daily gas equivalent production 2,347 MMcfe/d »

Preliminary Fourth…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

HBHC

Hancock Holding

$54.45

0.9 (1.68%)

16:35
01/17/18
01/17
16:35
01/17/18
16:35
Earnings
Hancock Holding reports Q4 EPS with items 64c, consensus 83c »

The fourth quarter of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

SLM

Sallie Mae

$11.49

0.02 (0.17%)

16:34
01/17/18
01/17
16:34
01/17/18
16:34
Earnings
Sallie Mae reports Q4 core EPS 10c, consensus 19c »

Reports Q4 net income…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

AR

Antero Resources

16:34
01/17/18
01/17
16:34
01/17/18
16:34
Hot Stocks
Antero Resources sees net daily production approximately 2.7 Bcfe/d in 2018 »

2018 Guidance and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

AM

Antero Midstream Partners

$30.95

-0.8 (-2.52%)

16:33
01/17/18
01/17
16:33
01/17/18
16:33
Hot Stocks
Antero Midstream Partners provides 2018 and long-term target guidance »

Antero Midstream provided…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

SBOW

SilverBow Resources

$31.48

0.52 (1.68%)

16:32
01/17/18
01/17
16:32
01/17/18
16:32
Hot Stocks
SilverBow Resources sees 2018 capital program of $245M-$265M »

SilverBow Resources…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 24

    Jan

RDN

Radian Group

$22.26

0.13 (0.59%)

16:31
01/17/18
01/17
16:31
01/17/18
16:31
Hot Stocks
Radian Group updates on capital actions »

Radian Group announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HES

Hess Corp.

$54.02

0.48 (0.90%)

16:30
01/17/18
01/17
16:30
01/17/18
16:30
Initiation
Hess Corp. initiated  »

Hess Corp. initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Feb

16:30
01/17/18
01/17
16:30
01/17/18
16:30
Options
Preliminary option volume of 23.6M today »

Preliminary option volume…

AAPL

Apple

$179.10

2.91 (1.65%)

, JUNO

Juno Therapeutics

$69.25

23.65 (51.86%)

16:25
01/17/18
01/17
16:25
01/17/18
16:25
General news
On The Fly: Top stock stories for Wednesday »

Stocks opened higher and…

AAPL

Apple

$179.10

2.91 (1.65%)

JUNO

Juno Therapeutics

$69.25

23.65 (51.86%)

CELG

Celgene

$102.02

-2.8 (-2.67%)

BLUE

bluebird bio

$175.25

11.9 (7.29%)

BLCM

Bellicum Pharmaceuticals

$8.45

-0.01 (-0.12%)

CLLS

Cellectis

$30.19

2.41 (8.68%)

BAC

Bank of America

$31.18

-0.06 (-0.19%)

GS

Goldman Sachs

$253.65

-4.81 (-1.86%)

BA

Boeing

$351.01

15.85 (4.73%)

ERJ

Embraer

$24.69

-0.09 (-0.36%)

GT

Goodyear Tire

$34.37

0.87 (2.60%)

PSTG

Pure Storage

$17.89

1.73 (10.71%)

F

Ford

$12.18

-0.92 (-7.02%)

FAST

Fastenal

$52.20

-3.24 (-5.84%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

  • 17

    Jan

  • 17

    Jan

  • 17

    Jan

  • 18

    Jan

  • 18

    Jan

  • 24

    Jan

  • 25

    Jan

  • 25

    Jan

  • 31

    Jan

  • 31

    Jan

  • 01

    Feb

  • 15

    Feb

  • 16

    Feb

  • 21

    Feb

  • 26

    Feb

  • 14

    Mar

  • 25

    Mar

PTC

PTC

$66.77

1.5 (2.30%)

16:23
01/17/18
01/17
16:23
01/17/18
16:23
Hot Stocks
Breaking Hot Stocks news story on PTC »

PTC up 5.7% afterhours…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

MRC

MRC Global

, DCP

DCP Midstream

$41.61

0.05 (0.12%)

16:23
01/17/18
01/17
16:23
01/17/18
16:23
Hot Stocks
MRC Global renews PVF distribution framework agreement with DCP Midstream »

MRC Global (MRC)…

MRC

MRC Global

DCP

DCP Midstream

$41.61

0.05 (0.12%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Feb

PLXS

Plexus

$64.36

0.59 (0.93%)

16:22
01/17/18
01/17
16:22
01/17/18
16:22
Earnings
Plexus sees Q2 GAAP diluted EPS 68c-78c, consensus 82c »

Sees Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

  • 07

    Feb

NMRK

Newmark

$16.06

0.07 (0.44%)

16:22
01/17/18
01/17
16:22
01/17/18
16:22
Hot Stocks
Newmark Knight Frank announces new venture with E Smith Legacy Holdings »

E Smith Legacy Holdings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Feb

NEOT

Neothetics

$1.92

0.0793 (4.31%)

16:21
01/17/18
01/17
16:21
01/17/18
16:21
Hot Stocks
Neothetics closes merger with Evofem »

Neothetics closed the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BKMU

BankMutual

$11.05

0.05 (0.45%)

16:20
01/17/18
01/17
16:20
01/17/18
16:20
Earnings
BankMutualreports Q4 EPS 4c, consensus 11c »

Excluding the after-tax…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OKE

Oneok

$59.41

0.61 (1.04%)

16:20
01/17/18
01/17
16:20
01/17/18
16:20
Hot Stocks
Oneok raises quarterly dividend 3% to 77c per share »

The dividend is payable…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.